Search Results - "MUNSTER, Pamela N"

Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer by Terranova-Barberio, Manuela, Pawlowska, Nela, Dhawan, Mallika, Moasser, Mark, Chien, Amy J., Melisko, Michelle E., Rugo, Hope, Rahimi, Roshun, Deal, Travis, Daud, Adil, Rosenblum, Michael D., Thomas, Scott, Munster, Pamela N.

“…Responses to immunotherapy are uncommon in estrogen receptor (ER)-positive breast cancer and to date, lack predictive markers. This randomized phase II study…”
Get full text

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor by YARDLEY, Denise A, ISMAIL-KHAN, Roohi R, MELICHAR, Bohuslav, LICHINITSER, Mikhail, MUNSTER, Pamela N, KLEIN, Pamela M, CRUICKSHANK, Scott, MILLER, Kathy D, LEE, Min J, TREPEL, Jane B

“…Entinostat is an oral isoform selective histone deacetylase inhibitor that targets resistance to hormonal therapies in estrogen receptor-positive (ER+) breast…”
Get full text

HDAC inhibition potentiates immunotherapy in triple negative breast cancer by Terranova-Barberio, Manuela, Thomas, Scott, Ali, Niwa, Pawlowska, Nela, Park, Jeenah, Krings, Gregor, Rosenblum, Michael D, Budillon, Alfredo, Munster, Pamela N

“…Triple-negative breast cancer (TNBC) represents a more aggressive and difficult subtype of breast cancer where responses to chemotherapy occur, but toxicity is…”
Get full text

Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas by Zill, Oliver A, Greene, Claire, Sebisanovic, Dragan, Siew, Lai Mun, Leng, Jim, Vu, Mary, Hendifar, Andrew E, Wang, Zhen, Atreya, Chloe E, Kelley, Robin K, Van Loon, Katherine, Ko, Andrew H, Tempero, Margaret A, Bivona, Trever G, Munster, Pamela N, Talasaz, AmirAli, Collisson, Eric A

“…Patients with pancreatic and biliary carcinomas lack personalized treatment options, in part because biopsies are often inadequate for molecular…”
Get more information

Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer by MUNSTER, Pamela N, MOORE, Amy P, ISMAIL-KHAN, Roohi, COX, Charles E, LACEVIC, Mensura, GROSS-KING, Margaret, PING XU, CARTER, W. Bradford, MINTON, Susan E

“…Chemotherapy-induced amenorrhea is a serious concern for women undergoing cancer therapy. This prospective randomized trial evaluated the use of…”
Get full text

Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies by Aggarwal, Rahul, Thomas, Scott, Pawlowska, Nela, Bartelink, Imke, Grabowsky, Jennifer, Jahan, Thierry, Cripps, Amy, Harb, Armand, Leng, Jim, Reinert, Anne, Mastroserio, Ilaria, Truong, Thach-Giao, Ryan, Charles J, Munster, Pamela N

“…Purpose This phase I trial evaluated epigenetic modulation of vascular endothelial growth factor (VEGF) and hypoxia-inducible factor by using a histone…”
Get full text

Histone deacetylase regulation of ATM-mediated DNA damage signaling by Thurn, K Ted, Thomas, Scott, Raha, Paromita, Qureshi, Ian, Munster, Pamela N

“…Ataxia-telangiectasia mutated (ATM) is a major regulator of the DNA damage response. ATM promotes the activation of BRCA1, CHK2, and p53 leading to the…”
Get full text

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma by DAUD, Adil I, DECONTI, Ronald C, HELLER, Richard, ANDREWS, Stephanie, URBAS, Patricia, RIKER, Adam I, SONDAK, Vernon K, MUNSTER, Pamela N, SULLIVAN, Daniel M, UGEN, Kenneth E, MESSINA, Jane L

“…Gene-based immunotherapy for cancer is limited by the lack of safe, efficient, reproducible, and titratable delivery methods. Direct injection of DNA into…”
Get full text

Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma by Rubenstein, James L., Geng, Huimin, Fraser, Eleanor J., Formaker, Paul, Chen, Lingjing, Sharma, Jigyasa, Killea, Phoebe, Choi, Kaylee, Ventura, Jenny, Kurhanewicz, John, Lowell, Clifford, Hwang, Jimmy, Treseler, Patrick, Sneed, Penny K., Li, Jing, Wang, Xiaomin, Chen, Nianhang, Gangoiti, Jon, Munster, Pamela N., Damato, Bertil

“…There is an unmet need for effective biological therapies for relapsed central nervous system (CNS) lymphoma. Lenalidomide is active in activated B-cell type…”
Get full text

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors by WONG, Kwok-K, FRACASO, Paula M, JONAS, Suzanne F, MEKHAIL, Tarek, ZACHARCHUK, Charles, VERMETTE, Jennifer, ABBAS, Richat, QUINN, Susan, POWELL, Christine, BURRIS, Howard A, BUKOWSKI, Ronald M, LYNCH, ThomasJ, MUNSTER, Pamela N, SHAPIRO, Geoffrey I, JÄNNE, Pasi A, EDER, Joseph P, NAUGHTON, Michael J, ELLIS, MatthewJ

“…Purpose: The dose-limiting toxicities, maximum tolerated dose, pharmacokinetic profile, and preliminary antitumor activity of neratinib (HKI-272), an…”
Get full text

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant by Pivonello, Rosario, Munster, Pamela N, Terzolo, Massimo, Ferrigno, Rosario, Simeoli, Chiara, Puglisi, Soraya, Bali, Utsav, Moraitis, Andreas G

“…Somatostatin exhibits an inhibitory effect on pituitary hormone secretion, including inhibition of growth hormone and adrenocorticotropic hormone (ACTH), and…”
Get full text

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy by Thomas, Scott, Munster, Pamela N

“…Abstract Histone deacetylase (HDAC) inhibitors are a novel class of anti-tumor agents with a potential role in the treatment of breast cancer. In ER-positive…”
Get full text

Cognitive functioning in breast cancer survivors: A controlled comparison by Jim, Heather S. L., Donovan, Kristine A., Small, Brent J., Andrykowski, Michael A., Munster, Pamela N., Jacobsen, Paul B.

“…BACKGROUND: The current study was performed to determine whether neuropsychologic functioning differs in breast cancer survivors 6 months after the completion…”
Get full text

Identifying Clinically Meaningful Fatigue with the Fatigue Symptom Inventory by Donovan, Kristine A., PhD, Jacobsen, Paul B., PhD, Small, Brent J., PhD, Munster, Pamela N., MD, Andrykowski, Michael A., PhD

“…Abstract The Fatigue Symptom Inventory has been used extensively to assess and measure fatigue in a number of clinical populations. The purpose of the present…”
Get full text

Commentary: GSK-3 Inhibition as a Therapeutic Approach Against SARs CoV2: Dual Benefit of Inhibiting Viral Replication While Potentiating the Immune Response by De Souza, Andre, Tavora, Fabio A., Mahalingam, Devalingam, Munster, Pamela N., Safran, Howard P., El-Deiry, Wafik S., Carneiro, Benedito A.

Get full text

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins by MARCHION, Douglas C, BICAKU, Elona, DAUD, Adil I, SULLIVAN, Daniel M, MUNSTER, Pamela N

“…Histone acetylation and deacetylation are crucial in the regulation of gene expression. Dynamic changes in gene expression may affect chromatin structure and,…”
Get full text

Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt by Thomas, Scott, Thurn, K Ted, Raha, Paromita, Chen, Stephanie, Munster, Pamela N

“…Hormonal therapy resistance remains a considerable barrier in the treatment of breast cancer. Activation of the Akt-PI3K-mTOR pathway plays an important role…”
Get full text

Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer by Guglin, Maya, Krischer, Jeffrey, Tamura, Roy, Fink, Angelina, Bello-Matricaria, Lauren, McCaskill-Stevens, Worta, Munster, Pamela N.

“…Trastuzumab is highly effective for human epidermal growth factor receptor type 2 (HER2)–positive breast cancer but is associated with a decline in left…”
Get full text

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma by Munster, Pamela N, Daud, Adil I

“…This review covers the preclinical and clinical activity of the novel camptothecin analog, karenitecin, in melanoma. While the camptothecins are widely used…”
Get more information

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial by DAUD, Adil I, DAWSON, Jana, MUNSTER, Pamela N, DECONTI, Ronald C, BICAKU, Elona, MARCHION, Douglas, BASTIEN, Sem, HAUSHEER, Frederick A, LUSH, Richard, NEUGER, Anthony, SULLIVAN, Daniel M

“…Purpose: The novel topoisomerase I inhibitor karenitecin (KTN) shows activity against melanoma. We examined whether histone deacetylase inhibition could…”
Get full text